News
TRAX ▲ +41.1% - First Tracks Biotherapeutics, Inc.
TRAX ▲ +41.1% - First Tracks Biotherapeutics, Inc.
$TRAX - First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
12-OCT-2026 07:00 AM ET
Share this post
More filings for $TRAX
TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026TRAX ▲ +5.0% - First Tracks Biotherapeutics, Inc.Oct 15, 2026TRAX ▼ -0.7% - First Tracks Biotherapeutics, Inc.Oct 11, 2026TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026TRAX - First Tracks Biotherapeutics, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $TRAX filing history →💬 Comments
Loading comments…
Leave a comment